216 related articles for article (PubMed ID: 16374818)
1. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
Bernitsas E; Wei W; Mikol DD
Ann Neurol; 2006 Jan; 59(1):206-9. PubMed ID: 16374818
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
[TBL] [Abstract][Full Text] [Related]
3. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A;
Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418
[TBL] [Abstract][Full Text] [Related]
4. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
5. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
6. B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients--preliminary study.
Luchowski P; Mitosek-Szewczyk K; Bartosik-Psujek H; Rubaj A; Jankiewicz M; Wojczal J; Szczepańska-Szerej A; Stelmasiak Z
Clin Neurol Neurosurg; 2009 Oct; 111(8):676-8. PubMed ID: 19632767
[TBL] [Abstract][Full Text] [Related]
7. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Hamzehloo A; Etemadifar M
Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351
[TBL] [Abstract][Full Text] [Related]
9. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
11. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
Galetta F; Franzoni F; Cervetti G; Cecconi N; Carpi A; Petrini M; Santoro G
Biomed Pharmacother; 2005 Dec; 59(10):541-4. PubMed ID: 16325366
[TBL] [Abstract][Full Text] [Related]
12. [Mitoxantrone].
Pericot I; Montalban X
Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
[TBL] [Abstract][Full Text] [Related]
13. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
Wexler LH
Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
Singhal BS; Geeta S; Hundalani SG; Menon S
Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
[TBL] [Abstract][Full Text] [Related]
15. [Immunosuppressive therapy of multiple sclerosis with mitoxantrone].
Mauch E; Kornhuber HH
Fortschr Neurol Psychiatr; 1993 Dec; 61(12):410-7. PubMed ID: 8112704
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone treatment of multiple sclerosis: safety considerations.
Cohen BA; Mikol DD
Neurology; 2004 Dec; 63(12 Suppl 6):S28-32. PubMed ID: 15623667
[TBL] [Abstract][Full Text] [Related]
17. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
[TBL] [Abstract][Full Text] [Related]
18. Overview and historical development of dexrazoxane.
Hellmann K
Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.
Langer SW; Thougaard AV; Sehested M; Jensen PB
Cancer Chemother Pharmacol; 2012 Feb; 69(2):573-6. PubMed ID: 22143379
[TBL] [Abstract][Full Text] [Related]
20. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]